Those are some compelling arguments and I have struggled with them myself....and that is why making National and International news last weekend was important. It provided a spotlight for leronlimab to validate itself. I/we all know the science is solid and now we have the attention to prove this on stage. There is little doubt left for me that CYDY doesn’t see $40+ at some point in the future ($40 being the low end of a BO).

While I agree that BP has and will continue to have a significant influence on the FDA and smaller biotechs, CytoDyn and leronlimab are not your typical biotech company or drug. It is rare to see a small company (much less OTC) make the transition from pre-revenue to even mid-market player. I don’t know that we will get there, but if there was ever a chance leronlimab has the ability to make this dream come true.....and if time runs out and BP scoops it up, the CytoDyn dream will die but leronlimab will still save many lives and make a lot of us millionaires in the process.

Best of luck and I hope everyone has a safe weekend.